Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 6/20 | 0.57 |
| ▸ | RAB9A | P51151 | 6/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | MT-CO2 | P00403 | 1/20 | 0.55 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | PARP1 | P09874 | 1/20 | 0.50 |
| ▸ | PLAAT3 | P53816 | 1/20 | 0.50 |
| ▸ | PLAAT5 | Q96KN8 | 1/20 | 0.50 |
| ▸ | PLAAT2 | Q9NWW9 | 1/20 | 0.50 |
| ▸ | PLAAT4 | Q9UL19 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3407189 | 0.88 | RAB9A (0.63) | NPC1RAB9ASMN1; SMN2ALDH1A1MT-CO2 | |
| SCHEMBL29858570 | 0.88 | RAB9A (0.63) | NPC1RAB9ASMN1; SMN2ALDH1A1MT-CO2 | |
| SCHEMBL3577771 | 0.86 | NPC1 (0.55) | NPC1RAB9ASMN1; SMN2ALDH1A1MT-CO2 | |
| SCHEMBL14606883 | 0.83 | GAA (0.48) | NPC1RAB9ASMN1; SMN2ALDH1A1POLB | |
| SCHEMBL2577570 | 0.77 | L3MBTL1 (0.64) | SMN1; SMN2ALDH1A1POLBKDM4ELMNA | |
| SCHEMBL10748316 | 0.77 | CRBN (0.56) | SMN1; SMN2ALDH1A1POLBKDM4ELMNA | |
| SCHEMBL2332195 | 0.76 | RAB9A (0.88) | NPC1RAB9ASMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL5055189 | 0.76 | CRBN (0.54) | SMN1; SMN2ALDH1A1POLBKDM4EHPGD | |
| SCHEMBL29922998 | 0.76 | CRBN (0.54) | SMN1; SMN2ALDH1A1POLBKDM4EHPGD | |
| SCHEMBL1585240 | 0.76 | SMN1; SMN2 (0.53) | NPC1RAB9ASMN1; SMN2ALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7678818-B2 | Anthranilamide and 2-amino-heteroarene-carboxamide compounds | HOFFMANN-LA ROCHE INC. (US) | 2010-03-16 | — | — | US | disclosed |
| US-20070219261-A1 | Anthranilamide and 2-amino-heteroarene-carboxamide compounds | HOFFMANN-LA ROCHE INC. | 2007-09-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070219261-A1 | Anthranilamide and 2-amino-heteroarene-carboxamide compounds | AADAT, AAAS, AADAC | NPC1 3237/4885RAB9A 1226/4885SMN1; SMN2 2333/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.